TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03728439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED before
Description: Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED interval
Description: Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED after
Description: Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
Study: NCT00553488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin (Humulin)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin (Humulin)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin (Humulin)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro (Humalog)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
Study: NCT03166995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural exercises
Description: The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
Study: NCT03381677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedicle Lengthening Osteotomy with Altum® Device
Description: Decompressive surgery via Pedicle lengthening osteotomy using Altum Device. Altum is intended for pedicle lengthening to correct degenerative lumbar spinal stenosis in the presence of a grade 1 degenerative spondylolisthesis. The Altum bone saw is designed for creating an osteotomy at the base of each pedicle. The Altum implant is designed for distraction of the pedicle osteotomy and for lengthening of the pedicles. Altum is appropriate for skeletally mature adults with symptomatic stenosis at one or two levels between L2-L5.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~1. DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~2. DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage.
Study: NCT02821351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio frequency (RF) Cardiac ablation
Description: Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
Study: NCT01622062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: 0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV and pERIG Favirab®
Description: 0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PVRV and pERIG Favirab®
Description: 0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
Study: NCT05164380

Intervention type: OTHER
Intervention: Picture naming tasks
Description: PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.

Intervention type: OTHER
Intervention: Picture naming tasks
Description: PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.
Study: NCT00002745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminocamptothecin
Description: 850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
Study: NCT03776708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation is defined as a quick, passive and forced manoeuvre applied to spinal joints, and sometimes followed by a characteristic cracking sound. It can be compared to a mobilisation, which is a passive manual therapy as well, but is applied slower and repetitively on the joints. Spinal manipulation has been shown to have a significant clinical impact in the treatment of musculoskeletal pain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires
Study: NCT06045052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.
Study: NCT02630680

Intervention type: DRUG
Intervention: Eziclen®/Izinova®
Study: NCT00263367

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric Oxygen
Description: Hyperbaric Oxygen at 1.3 ATA for one hour
Study: NCT04080037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality IQ Patient Simulations
Description: Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication.
Study: NCT00925678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-3025

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03771794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReguRate neurostimulation
Description: Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ReguRate neurostimulation
Description: Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode
Study: NCT06170177

Intervention type: PROCEDURE
Intervention: Radical Cystectomy
Description: A radical cystectomy is an operation to remove the whole bladder
Study: NCT03942692

Intervention type: OTHER
Intervention: Phone call questionnaire
Description: Questionnaire for parents of subject about :~* the frequency of consultations with an allergist~* the information of the general practitioner or pediatrician~* the prescription of epinephrin auto-injector~* the frequency of renewal of epinephrin auto-injector~* the specialty of doctor who prescribed the renewal~* the implementation of specific measures in schools~* the frequency of renewal of specific measures in schools~* the number of recurrence of anaphylactic reaction~* the use of medical advice in case of recurrence of anaphylactic reaction
Study: NCT00071461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d.
Study: NCT03556787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPI 1000013 (Dr Scholls Insole)
Description: Full length foam insole
Study: NCT04288505

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIRTUAL REALITY application
Description: application on virtual reality headset
Study: NCT01865747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (Afinitor) tablets
Study: NCT01133418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Progressive Attention Training
Description: Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator Cognitive Training
Description: Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
Study: NCT00022581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03468478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: sirolimus combined to reduced dose of tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus combined to reduced dose of tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: Control arm: mycophenolate combined to regular tacrolimus
Study: NCT00553488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro (Humalog)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
Study: NCT02233699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00827710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: point of care patient report cards
Description: gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: point of care patient report cards
Description: gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider performance report card
Description: Gives provider feedback on performance on their diabetes panel of patients and includes patient level data

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider performance report card
Description: Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
Study: NCT01268852

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Damon self ligating orthodontic bracket
Description: Orthodontic treatment with Damon self ligating bracket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insignia self ligating orthodontic bracket
Description: Orthodontic treatment with Insignia self ligating bracket
Study: NCT03854721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAX014
Description: Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
Study: NCT06171854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: cabozantinib in patients with refractory mCRC
Study: NCT02050334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC100
Description: CC100 reconstituted in diluent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC100
Description: CC100 reconstituted in diluent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diluent. Amount to match CC100 dose.
Study: NCT01583413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily SAT & SBT
Description: Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
Study: NCT01290510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid sodium salt
Description: Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
Study: NCT02410447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocused shock wave therapy (DUOLITH® SD1)
Study: NCT01625871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tablets artemether/lumefantrine
Description: six doses of oral tablets of artemether/lumefantrine
Study: NCT03869762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xgeva
Description: Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xtandi
Description: Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression.
Study: NCT03578627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BioBehavioral Intervention
Description: Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints-recurrence, disease free interval) might be affected.
Study: NCT02788721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 single dose
Description: GLPG2451 oral suspension, single ascending doses, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral suspension, daily
Study: NCT02983760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Planar V/Q-based strategy
Description: Strategy based on planar pulmonary scintigraphy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CTPA-based strategy
Description: Strategy based on pulmonary angiography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V/Q SPECT-based strategy
Description: Strategy based on pulmonary tomoscintigraphy
Study: NCT02990130

Intervention type: OTHER
Intervention: Observational
Study: NCT03295734

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Twice weekly centered based aerobic exercise + 3/week home-based walking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Twice weekly centered based aerobic exercise + 3/week home-based walking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Twice weekly centered based aerobic exercise + 3/week home-based walking

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 4 mg qd titrated to 8 mg qd perindopril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 mg qd titrated to 100 qd losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: 12.5 mg qd titrated to 25 qd HCTZ
Study: NCT03124160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mona Lisa® NT Cu380 Mini
Description: copper intrauterine device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ParaGard® TCu380A
Description: copper intrauterine device
Study: NCT00921661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0005 (aflibercept)
Description: IV infusion
Study: NCT01750060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study: NCT04701450

Intervention type: OTHER
Intervention: digital consent
Description: the patient's medical history is taken in a digital survey, information about the anaesthetic procedure is aided by video material
Study: NCT02778152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser depilation
Description: Laser depilation of natal cleft (pilonidal region)
Study: NCT02213315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg Mavrilimumab
Description: 100mg Mavrilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg mavrilimumab
Description: 150mg mavrilmumab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01272908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg intravenously on Days 1 and 15
Study: NCT02482142

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Effect of phosphorus
Description: Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effect of phosphorus
Description: Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Effect of phosphorus
Description: Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effect of phosphorus
Description: Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effect of phosphorus
Description: Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
Study: NCT00527826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol / Fluticasone (50/500 µg) BID fixed combination
Description: comparator
Study: NCT01064648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given orally